Omalizumab to Treat Hyper-IgE (Job's) Syndrome

NCT00260702 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

1

Enrollment

NIH

Sponsor class

Conditions

Hyper-IgE Syndrome
Job's Syndrome

Interventions

DRUG: Omalizumab (Xolair)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)